Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis

• DOI: 10.1126/scitranslmed.3007355
• Publication Date: 2013-12-04T19:25:07Z
• Authors: Srinivasa P. S. Rao; Suresh B. Lakshmi...; Ravinder R. Kondr...; Maxime Herve; Luis R. Camacho; Pablo Bifani; Sarath K. Kalapala; Jan Jiricek; Ng L. Ma; Bee H. Tan; Seow H. Ng; Mahesh Nanjundappa; Sindhu Ravindran; Peck G. Seah; Pamela Thayalan; Siao H. Lim; Boon H. Lee; Anne Goh; Whitney S. Barnes; Zhong Chen; Kerstin Gagaring; Arnab K. Chatterjee; Kevin Pethe; Kelli Kuhen; John Walker; Gu Feng; Sreehari Babu; Lijun Zhang; Francesca Blasco; David Beer; Margaret Weaver; Veronique Dartois; Richard Glynne; Thomas Dick; Paul W. Smith; Thierry T. Diagana; Ujjini H. Manjunatha
• Keywords: 0301 basic medicine; Indoles; Antitubercular Agents; 610; Administration, Oral; Biological Availability; Microbial Sensitivity Tests; Mice; 03 medical and health sciences; Dogs; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; 616; Tuberculosis, Multidrug-Resistant; Animals; Humans; Rats, Wistar; Mice, Inbred BALB C; Dose-Response Relationship, Drug; Membrane Transport Proteins; Mycobacterium tuberculosis; Rats; 3. Good health; Disease Models, Animal; Injections, Intravenous

The small-molecule indolcarboxamide is a potential drug candidate for treating multidrug-resistant tuberculosis.